BPI-16350

Chemical compound From Wikipedia, the free encyclopedia

BPI-16350 is a small molecule CDK4/6 inhibitor that is being studied for the treatment of cancer.[1][2] It has a similar structure to abemaciclib but is more selective for CDK4/6 over CDK9 according to preclinical research.[3]

Other namesBPI16350
Legal status
  • Investigational
CAS Number
PubChem CID
Quick facts Clinical data, Other names ...
BPI-16350
Clinical data
Other namesBPI16350
Legal status
Legal status
  • Investigational
Identifiers
  • N-[5-[(4-Ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-8-yl)pyrimidin-2-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC28H32F2N8
Molar mass518.617 g·mol−1
3D model (JSmol)
  • CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C6N5C(CCC6)C)F
  • InChI=1S/C28H32F2N8/c1-3-36-9-11-37(12-10-36)17-19-7-8-24(31-15-19)33-28-32-16-22(30)26(35-28)20-13-21(29)27-23(14-20)38-18(2)5-4-6-25(38)34-27/h7-8,13-16,18H,3-6,9-12,17H2,1-2H3,(H,31,32,33,35)
  • Key:XOJPAVACYRFOBK-UHFFFAOYSA-N
Close

References

Related Articles

Wikiwand AI